3 Pharmaceutical Stocks to Sell Now

by Portfolio Grader | May 24, 2013 10:05 am

This week, the ratings of three Pharmaceutical stocks on Portfolio Grader[1] are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

VIVUS Inc.’s (NASDAQ:VVUS[2]) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. VVUS also rates an F in Portfolio Grader’s specific subcategory of Equity. As of May 24, 2013, 26.2% of outstanding VIVUS Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VVUS stock[3].

Cempra Holdings LLC (NASDAQ:CEMP[4]) experiences a ratings drop this week, going from last week’s C to a D. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. To get an in-depth look at CEMP, get Portfolio Grader’s complete analysis of CEMP stock[5].

Corcept Therapeutics (NASDAQ:CORT[6]) earns an F (“strong sell”) this week, moving down from last week’s grade of D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For a full analysis of CORT stock, visit Portfolio Grader[7].

Louis Navellier’s proprietary Portfolio Grader[8] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[9].

Source URL: https://investorplace.com/2013/05/3-pharmaceutical-stocks-to-sell-now-vvus-cemp-cort-8/

---